Swiss healthcare solutions provider Novartis has agreed to purchase AveXis for $8.7bn.
Novartis has formed a subsidiary named Novartis Merger Corporation, which will buy all outstanding shares of AveXis for $218 a share, as part of the acquisition.
Go deeper with GlobalData
The acquisition has been approved by the boards of both companies and will be completed through available cash and short-term borrowing.
Based in the US, AveX is a gene therapy company, which has ongoing clinical trials on the spinal muscular atrophy (SMA), an inherited neurodegenerative disease.
The acquisition will strengthen Novartis’ position in the gene therapy and neuroscience space.
AveXis has appointed Goldman Sachs & Co. and Centerview Partners as financial advisors, and Cravath, Swaine and Moore and Cooley as legal advisers for the transaction.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSwiss healthcare company Roche has completed the acquisition of Flatiron Health for $1.9bn.
Flatiron will continue to operate as a separate legal entity and also maintain the existing business model and partnership network, upon the completion of acquisition.
Based in the US, Flatiron Health provides oncology-specific electronic health record software products and develops real-world evidence to aid cancer research.
Alexion Pharma Nordics Holding (Alexion) has agreed to purchase all outstanding shares of Wilson Therapeutics for Skr7.1bn ($852.07m) through a tender.
Alexion offered Skr232 per share in cash for each share of Wilson Therapeutics, as part of the acquisition.
The company has appointed BofA Merrill Lynch Asset Holdings as lead financial adviser and Advokatfirman Cederquist as legal adviser for the transaction.
Alexion is a subsidiary of American pharmaceutical company Alexion Pharmaceuticals, while Wilson Therapeutics is a biopharmaceutical company.
Both companies involved in the acquisition are based in Sweden.
Swiss biopharmaceutical company Promethera Biosciences has acquired Baliopharm.
The target company, also based in Switzerland, is involved in the development of targeted biological therapies.
The acquisition will help Promethera Biosciences to reinforce its therapeutic strategy in Non-alcoholic steatohepatitis (NASH) with tumour necrosis factor receptor 1 (TNF-R1) antibody drug candidates.
NanoCarrier has agreed to purchase a 5.23% share in Gene Techno Science for ¥1.2bn ($11.4m).
NanoCarrier will acquire 500,000 shares of Gene Techno Science as part of the transaction.
Based in Japan, NanoCarrier is a biopharmaceutical products provider.
